Related Experiment Video
Updated: Sep 13, 2025
Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells
Published on: March 7, 2025
Immune evasion in cancer: mechanisms and cutting-edge therapeutic approaches
Muhammad Tufail1, Can-Hua Jiang1,2,3,4, Ning Li5,6,7,8
1Department of Oral and Maxillofacial Surgery, Center of Stomatology, Xiangya Hospital, Central South University, Changsha, China.
Abstract:
Immune evasion represents a significant challenge in oncology. It allows tumors to evade immune surveillance and destruction, thereby complicating therapeutic interventions and contributing to suboptimal patient outcomes. This review addresses the critical need to understand how cancers evade immune surveillance. It aims to provide a comprehensive overview of strategies of tumors to escape immune detection by examining tumor-induced immune suppression, immune checkpoint regulation, and genetic and epigenetic influences. Moreover, it explores the dynamic role of the tumor microenvironment (TME) in fostering immune resistance and highlights the impact of metabolic reprogramming on immune suppression. Additionally, this review focuses on how tumor heterogeneity influences immune evasion and discusses the limitations of current immunotherapies. The role of key signaling pathways, including programmed cell death protein 1/programmed cell death ligand 1 (PD-1/PD-L1), cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4), transforming growth factor-β (TGF-β), nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB), and cyclic GMP-AMP synthase-stimulator of interferon genes (cGAS-STING) is analyzed to elucidate their contributions to immune escape. Emphasizing the complexities of immune evasion, this review underscores the importance of personalized approaches and the integration of multi-omics data to combat therapeutic resistance. Furthermore, it discusses novel and emerging therapeutic strategies, such as bispecific antibodies, oncolytic viruses, and nanotechnology-driven immunotherapies, showcasing innovative avenues in cancer treatment. The significance of this review lies in its potential to guide future research and innovations in immunotherapy, ultimately improving patient outcomes and advancing our understanding of cancer immunology.
Insights
Cancer immune evasion hinders treatment by allowing tumors to hide from the immune system. Understanding tumor strategies and the tumor microenvironment is key to developing effective cancer immunotherapies.
Area of Science:
- Oncology
- Immunology
- Cancer Biology
Background:
- Immune evasion is a major obstacle in cancer treatment, leading to therapeutic resistance and poor patient outcomes.
- Tumors employ diverse strategies to evade immune surveillance, necessitating a deeper understanding of these mechanisms.
Purpose of the Study:
- To provide a comprehensive review of tumor immune evasion strategies.
- To analyze the role of the tumor microenvironment (TME) and metabolic reprogramming in immune suppression.
- To discuss the impact of tumor heterogeneity and limitations of current immunotherapies.
Main Methods:
- Literature review of immune evasion mechanisms in cancer.
- Analysis of key signaling pathways involved in immune escape (e.g., PD-1/PD-L1, CTLA-4, TGF-β, NF-κB, cGAS-STING).
- Exploration of emerging therapeutic strategies and the integration of multi-omics data.
Main Results:
- Tumors utilize immune suppression, immune checkpoint regulation, genetic/epigenetic factors, and metabolic reprogramming to evade immune detection.
- Tumor microenvironment dynamics and heterogeneity significantly influence immune resistance.
- Current immunotherapies face limitations, highlighting the need for advanced approaches.
Conclusions:
- A thorough understanding of immune evasion mechanisms is crucial for improving cancer immunotherapy.
- Personalized treatment strategies integrating multi-omics data are essential for overcoming therapeutic resistance.
- Novel therapies like bispecific antibodies, oncolytic viruses, and nanotech-based immunotherapies offer promising avenues for cancer treatment.
More Related Videos
07:29Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment
Published on: April 22, 2019
08:02In Vivo Immunogenicity Screening of Tumor-Derived Extracellular Vesicles by Flow Cytometry of Splenic T Cells
Published on: September 23, 2021
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
01:27Tumor Immunotherapy
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:56Treatment Resistant Cancers
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
01:30Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...